Maze Therapeutics, Inc. (MAZE) vs Ultragenyx Pharmaceutical Inc. (RARE)
A side-by-side comparison of Maze Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MAZE
Maze Therapeutics, Inc.
$26.16HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
RARE
Ultragenyx Pharmaceutical Inc.
$14.57HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — MAZE vs RARE
growth of $100 · dividends reinvested · last 2yMAZE +65.7% (+28.7%/yr)RARE -65.9% (-41.6%/yr)MAZE compounded faster over this window
MAZE RARE
MAZE vs RARE: by the numbers
- •MAZE is the larger company ($1.45B vs $1.43B market cap).
- •Both run net losses; RARE's is the smaller (-81.79% vs -667.95% net margin).
Metrics side by side
Valuation
| Metric | MAZE | RARE |
|---|---|---|
| P/S ratio | 72.39 | 2.00 |
| P/B ratio | 3.20 | N/A |
Profitability
| Metric | MAZE | RARE |
|---|---|---|
| Gross margin | 0.00% | 83.12% |
| Operating margin | 0.00% | -73.77% |
| Net margin | -667.95% | -81.79% |
| ROE | -29.48% | N/A |
| ROIC | -28.63% | -53.48% |
Growth (annualized)
| Metric | MAZE | RARE |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 14.81% |
| Total return CAGR (5Y) | N/A | -30.14% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.